



EXPRESS MAIL CERTIFICATE - LABEL NO EV 291 443 766 US

I hereby certify that this correspondence is being deposited with the United States EXPRESS MAIL Service as Express Mail in an envelop addressed to: Commissioner for Patents, Alexandria VA 22313, on June 30, 2003

By:

Lena Cheung

Date: June 30, 2003

In the event that this paper is late filed and a necessary Petition for an Extension of Time is not concurrently filed herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee.

#24  
9/12/03  
RECEIVED  
JUL 08 2003  
TECH CENTER 1600/2003

JG-RP-4796/500561.20065

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Claudia Cherney STEWART

Group: 1617

Serial No.: 09/330,629

Examiner: S. HUI

Filing Date: June 11, 1999

Customer No: 026418

For: METHOD OF HIV AND HPV PROPHYLAXIS


Commissioner for Patents  
Washington, D. C. 20231

**RESPONSE**

Sir:

This is in response to the Office Action mailed December 31, 2002,  
please amend the claims as follows: Amend claim 41 as shown:

41. (currently amended) A method for prophylactically reducing the risk of transmission of Human Immunodeficiency Virus infection to a recipient and protecting the recipient from infection with Human Immunodeficiency Virus infection comprising topically applying a Human Immunodeficiency Virus infection prophylactic effective amount to that site on the recipient which is ~~likely to be exposed~~ subject to exposure to Human Immunodeficiency Virus infection a composition comprising a Human Immunodeficiency Virus infection prophylactic effective amount of a compound having the structure



wherein each


A is the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;

*DI*  
Y is the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure  $\text{R}-\text{C}(=\text{O})-$  wherein R is hydrogen, an alkoxide group, an alkyl group, or OH;

B is the same or different and each is hydrogen or an alkyl group;

$\text{Z}^-$  is a soluble, pharmaceutically acceptable negative ion; and

X is the same or different and is an axial ligand selected from the group consisting of moieties having the formula:



wherein  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are the same or different and may be hydrogen or lower alkyl having from 1 to 4 carbon atoms;

with the proviso that  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are of a sufficiently small size so as not to prohibit the attachment of the axial ligand to the Co atom due to steric hindrance.